Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073554 · ClinicalTrials.gov registry record · Phase 2
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
A Phase 2 study of Thrombosis and Peripheral Vascular Diseases, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00073554 is a Phase 2 study of Thrombosis and Peripheral Vascular Diseases that has completed, run by ARCA Biopharma. The registered enrollment target is 100 participants, below the 467-participant average among 28 other Thrombosis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00073554, a Phase 2 study of Thrombosis and Peripheral Vascular Diseases, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).
Conditions Studied
Interventions
- DRUG Alfimeprase
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073554
The ClinicalTrials.gov registry entry for NCT00073554 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 467-participant average among 28 other Thrombosis trials with a reported enrollment target (79% lower). The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Alfimeprase is the first listed.
NCT00073554 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00073554 about?
NCT00073554 is a clinical study titled "Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion". This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).
What is the current status of trial NCT00073554?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2003-06.
What conditions does trial NCT00073554 study?
This clinical trial studies the following conditions: Thrombosis, Peripheral Vascular Diseases, Arterial Occlusive Diseases.
What interventions are being tested in trial NCT00073554?
The interventions under investigation include: Alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00073554?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073554 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
COMPLETED · Phase 2
-
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
COMPLETED · Phase 2
-
Study Of Angiomax In Infants Under Six Months With Thrombosis
COMPLETED · Phase 2
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.